Catalog No.
RVV08803
Expression system
Mammalian Cells
Species reactivity
Human papillomavirus type 16
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Applications
ELISA, Neutralization, WB
Target
L1, Major capsid protein L1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03101
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
H16.8A9
Note
For research use only.
Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16., PMID:29959021
L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037
VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris., PMID:30091403
Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156
A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses., PMID:30360122
Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935
Post-treatment human papillomavirus antibody kinetics in cervical cancer patients., PMID:30955486
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry., PMID:30996086
Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity., PMID:31147274
Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein., PMID:31381497
Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines., PMID:31994744
Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760
The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease., PMID:32133000
Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304
DRH1 - a novel blood-based HPV tumour marker., PMID:32535546
Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women., PMID:32727491
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963
Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347
Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test., PMID:33249381
Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test"., PMID:33254024
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485
Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568
Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433
In silico prediction of T-cell and B-cell epitopes of human papillomavirus type 16 L1 protein., PMID:33624357
Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291
Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen., PMID:33650709
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456
The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649
Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy., PMID:34635698
Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer., PMID:34642315
Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway., PMID:35619167
RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027
Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice., PMID:36679860
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181
Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus., PMID:36922453
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice., PMID:37175776
Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448
Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Mycobacterium tuberculosis Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice., PMID:37896900
A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency., PMID:38340596
Prevalence of HPV16 L1 protein in oral biopsies: A diagnostic study from Ecuador., PMID:39018933
Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16., PMID:39453911
[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350
Molecular epidemiology of human papillomavirus variants in cervical cancer in India., PMID:39913513
A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies., PMID:40197040
HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes., PMID:40236113
All-atom MD simulations of the HPV16 capsid., PMID:40475506
For research use only. Not for human or drug use.
